Phase 2 Alzheimer's Disease Trial, Recruiting NCT07007208 Sponsor: University Hospital, Toulouse Condition: Alzheimer's Disease
Back to Alzheimers Disease

Phase 2 Alzheimer's Disease Trial, Recruiting

NCT07007208
Recruiting Phase 2

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who are already taking part in the INSPIRE-T research cohort (a separate study group).
  • People whose memory and thinking abilities have been assessed as normal.
  • People who scored 27 or higher out of 30 on a standard memory and thinking test called the Mini-Mental State Examination.
  • People who have normal vision, whether with or without glasses or contact lenses.
  • People who have normal movement and physical coordination skills.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People for whom an MRI scan is not medically safe or suitable (for example, those with certain metal implants).
  • People who have had a known allergic reaction to the PET scan drug used in this trial, called [18F] Flortaucipir, or to any of its ingredients.
  • People who have an eye condition that would make it difficult to perform eye-tracking or eye movement measurements.
  • People who have a diagnosed neurological or psychiatric condition.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026

Contact this trial

Phone: +33 (0)562746169

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 January 2026
Est. completion
31 January 2029

Where this trial is recruiting

🇫🇷 France

Primary endpoints

diagnostic capabilities of Locus Coeruleus biomarkers for a positive PET-Tau exam

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov